LIFERIVER(SH:688317) Zhi Tong Cai Jing·2026-01-22 07:57Core Viewpoint - Zhijiang Biology (688317.SH) forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -32 million and -47 million yuan, indicating a significant loss compared to the previous year [1] Financial Performance - The expected net profit loss represents an increase in losses by 80.4621 million to 95.4621 million yuan compared to the same period last year, reflecting a year-on-year reduction in losses of 63.13% to 74.89% [1] Reasons for Loss - The primary reasons for the company's performance losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate for self-produced reagent products to 13%, resulting in decreased revenue [1] - Additional factors contributing to the losses include a decline in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1]